靶向性超抗原EGF-SEA融合基因的构建及表达

谢洋; 彭韶平; 廖志莹; 刘家峰; 刘雪梅; 陈伟峰

doi:10.13201/j.issn.1001-1781.2014.09.015

靶向性超抗原EGF-SEA融合基因的构建及表达

- 赣南医学院第一附属医院耳鼻咽喉科(江西赣州, 341000)
基金项目:
江西省卫生厅科技计划 (No:20091204)

详细信息

通讯作者: 彭韶平, E-mail:psphns@126.com

中图分类号: R739.6

收稿日期: 2013-10-23

Construction and expression of the targeting super-antigen EGF-SEA fusion gene

- Department of Otolaryngology, the First Hospital of Gannan Medical University, Ganzhou, 341000, China

More Information

Corresponding author: PENG Shaoping, E-mail: psphns@126.com

Received Date: 23 October 2013

摘要

摘要: 目的:构建金黄色葡萄球菌肠毒素A (SEA)和表皮生长因子(EGF)表达载体。方法:利用PCR及RT-PCR技术分别克隆出SEA基因及EGF基因片断,以经过改良优化的桥式PCR将2个基因融合,再转入表达载体pET-44,经诱导剂诱导后分泌SEA-EGF融合蛋白。结果: 所得SEA、EGF基因测序结果示与GENEBANK中公布的标准序列一致,且成功融合SEA-EGF基因并成功导入表达载体。结论:该研究成功构建了SEA-EGF表达载体,为进一步研究SEA-EGF融合蛋白抗头颈肿瘤靶向免疫治疗奠定了基础。
- 金黄色葡萄球菌肠毒素A /
- 表皮生长因子 /
- 超抗原 /
- 靶向治疗
Abstract: Objective:To construct expression vector for the SEA-EGF fusion gene.Method:Clone the SEA gene and the EGF gene segment with PCR and RT-PCR independently, and connect this two genes by the bridge PCR.Insert the fusion gene EGF-SEA into the expression vector PET-44. Induced the secretion of the fusion protein SEA-EGF by the antileptic.Result:The gene fragment encoding EGF and SEA mature peptide was successfully cloned. The fusion gene EGF-SEA was successfully constructed and was inserted into expression vector.Conclusion:The new recombinant expression vector for fusion gene EGF-SEA is specific for head and neck cancer,laid the foundation for the further study of fusion protein SEA-EGF targeting immune therapy in head and neck tumors.
- staphylococcus aureus enterotoxin A /
- epidermal growth factor /
- superantigen /
- targeted therapy

HTML全文

参考文献(7)

[1]	HEDLUND G, DOHLSTEN M, PETRSSON C, et al.Superantigen-based turmor theraphy in vivo activation of cytotoxic T cell[J].Cancer Immunol Immuother, 1993, 36:89-91.
[2]	ARAD G, LEVY R, KAEMPFER R.Superantigen concomitantly induces Th1 cytokine genes and the ability to shut off the irexpressionon reexposure to superantigen[J].Immunol Lett, 2002, 82:75-77.
[3]	BOURHIS J.Epidermal growth factor receptor (EGF) in head and neck cancers[J].Bull Cancer, 2007, 94 (7Suppl):189-191.
[4]	BALABAN N, RASOOLY A.Staphylococcal enterotoxins[J].Int J Food Microbiol, 2000, 61:1-10.
[5]	SHAW D M.A phaseⅡstudy of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma[J].Br J Cancer, 2007, 96:567-574.
[6]	ORSBERG G.Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen[J].Br J Cancer, 2001, 85:129-136.
[7]	ILBACK N G.A new screening model for safety evaluation of superantigen-antibody recombinant fusion proteins (mAb Fab-SEA/E) using telemetric monitoring in conscious rabbits[J].J Pharmacol Toxicol Methods, 2002, 48:31-39.